SGLT2 Inhibitors and HFpEF: A Promise Fulfilled?
Published: 05 October 2022
-
Views:
203742
-
Likes:
7
-
Views:
203742
-
Likes:
7
-
24m 59s
-
20m 45sPart 6 Q&A and Panel Discussion
-
4m 11sPart 1 Welcome and Opening Remarks Shelley Zieroth, Carolyn Lam, Scott Solomon, John JV McMurray, Subodh Verma
Overview
This broadcast 'SGLT2 Inhibitors and HFpEF: A Promise Fulfilled?' looks at the latest results from clinical trials studying pharmacotherapies in people with HFpEF, and current and emerging approaches in HFpEF diagnosis.
Dr Shelley Zieroth (St Boniface Hospital, CA) moderates proceedings, and is joined by an outstanding faculty, Prof Carolyn Lam (National Heart Centre, SG), Prof John McMurray (University of Glasgow, UK) Dr Scott Solomon (Brigham and Women's Hospital, US), and Dr Subodh Verma (St. Michael's Hospital, Toronto, CA), for a series of insightful presentations and discussions.
Note, the live version of this session was CME accredited; this on-demand version is not.
Learning Objectives
- To outline current and emerging approaches in HFpEF diagnosis
- To describe the latest results from clinical trials studying pharmacotherapies in people with HFpEF
- To explain how to practically personalise HFpEF management with established and novel drugs
Target Audience
- Primary Care Physicians
- Endocrinologists
- Nephrologists
- Cardiologists
- Nurses
- Pharmacists
- Dietitians
- Diabetes Educators
More from this programme
Part 1
Welcome and Opening Remarks
| 1 session | |
| Welcome and Opening Remarks | Watch now |
Part 2
HFpEF: Unraveling the Mysteries of a Recalcitrant Medical Problem
Part 3
SGLT2i in the Treatment of HFpEF: Have They Delivered in Clinical Trials?
Part 4
From DAPA-HF to DELIVER: Does Ejection Fraction Really Matter?
Part 5
From Paper to Practice - Practical Tips for Physicians
Part 6
Q&A and Panel Discussion
| 1 session | |
| Q&A and Panel Discussion | Watch now |
Faculty Biographies
Carolyn Lam
Professor and Senior Consultant
Prof Carolyn Lam is a Senior Consultant at the Department of Cardiology and Director of Women's Heart Health at the National Heart Centre Singapore, having pioneered the first Women’s Heart Clinic in Singapore. Prof Lam is a world-renowned specialist in heart failure (particularly heart failure with preserved ejection fraction [HFpEF]). Her work in the PARAGON-HF and EMPEROR-Preserved trials led to the first FDA-approved treatment for HFpEF and the first robustly positive clinical outcomes trial in HFpEF to-date.